The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

Leland Graves III, MD

Overview

The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).

Research subjects participation is about 6 months. Subjects will give themselves daily injections of teriparatide after instruction on technique.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Osteoporosis

Interventions

teriparatideDRUG

Teriparatide

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide Exclusion Criteria: * Patients with diabetes mellitus * current smokers * patients with a history of organ transplantation * Patients currently of previously on glucocorticoid therapy within the past year * Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater) * Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis * History of radiation therapy * Patients pregnant or nursing * History of bone metastasis or skeletal malignancies * History of hypercalcemia

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Outcomes

Primary Outcomes

The study measures changes in vascular compliance with teriparatide 1 hour, 3 months, and 6 months after initiating teriparatide. Osteoprotegerin and RANKL levels

Time frame: baseline, 3, and 6 months

Secondary Outcomes

CRP levels

Time frame: Baseline and at 6 months of therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.